Raloxifene therapy inhibits osteoclastogenesis during the alveolar healing process in rats

Archives of Oral Biology

Volumn 56, Issue 10, 2011, Pages 984-990

  Luvizuto, Eloá R ^a   Dias, Sheila S M D ^a   Okamoto, Tetuo ^b   Dornelles, Rita C M ^a   Okamoto, Roberta ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSIDADE DO SAGRADO CORAÇÃO   (Brazil)

Author keywords

Alveolar healing process; Bone; Oestrogen; OPG; Osteoblasts; Osteoclasts; Osteoporosis; Ovariectomy; Raloxifene; RANKL; TRAP

Indexed keywords

ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; ESTRADIOL; ESTROGEN; ISOENZYME; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TARTRATE-RESISTANT ACID PHOSPHATASE; TNFRSF11B PROTEIN, RAT;

ANIMAL; ARTICLE; BONE DENSITY; COMPARATIVE STUDY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; FIBROBLAST; IMMUNOHISTOCHEMISTRY; JAW; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OVARIECTOMY; PATHOLOGY; RANDOMIZATION; RAT; TIME; TOOTH EXTRACTION; TOOTH SOCKET; WISTAR RAT; WOUND HEALING;

ACID PHOSPHATASE; ALVEOLAR PROCESS; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FIBROBLASTS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; OSTEOPROTEGERIN; OVARIECTOMY; RALOXIFENE; RANDOM ALLOCATION; RANK LIGAND; RATS; RATS, WISTAR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS; TOOTH EXTRACTION; TOOTH SOCKET; WOUND HEALING;

RATTUS;

EID: 80053575768     PISSN: 00039969     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archoralbio.2011.03.015     Document Type: Article

References (39)

1. B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, and H.K. Genant Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 7 1999 637 645 (Pubitemid 29384151)
2. S.R. Cummings, S. Eckert, K.A. Krueger, D. Grady, T.J. Powles, and J.A. Cauley The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation JAMA 281 23 1999 2189 2197 (Pubitemid 29275701)
3. E. Barrett-Connor, D. Grady, A. Sashegyi, P.W. Anderson, D.A. Cox, and K. Hoszowshi Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial JAMA 287 7 2002 847 857 (Pubitemid 34252031)
4. W.S. Simonet, D.L. Lacey, C.R. Dunstan, M. Kelley, M.S. Chang, and R. Luthy Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 2 1997 309 319 (Pubitemid 27199902)
5. D.L. Lacey, E. Timms, H.-L. Tan, M.J. Kelley, C.R. Dunstan, and T. Burgess Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 2 1998 165 176 (Pubitemid 28180851)
6. R.A. Evans, C.R. Dunstan, and D.J. Baylink Histochemical identification of osteoclasts in undecalcified sections of human bone Miner Electrolyte Metab 2 1979 179 185
7. C. Minkin Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function Calcif Tissue Int 34 3 1982 285 290 (Pubitemid 12060442)
8. National Research Council. Guide for the care and use of laboratory animals. DHHS publication no. (NIH) 85-23 (rev.). Department of Health and Human Services, NRC, Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources; 1985.
9. H.B. Waynforth Experimental and surgical techniques in the rat 1980 Academic Press New York 161 163
10. T. Okamoto, and M.C. Russo Wound healing following tooth extraction: histochemical study in rats Rev Fac Odontol Araatuba 2 2 1973 153 169
11. E.R. Luvizuto, T.P. Queiroz, S.M. Dias, T. Okamoto, R.C. Dornelles, and I.R. Garcia Jr. Histomorphometric analysis and immunolocalization of RANKL and OPG during the alveolar healing process in female ovariectomized rats treated with oestrogen or raloxifen Arch Oral Biol 55 1 2010 52 59
12. E.R. Luvizuto, S.M. Dias, T.P. Queiroz, T. Okamoto, I.R. Garcia Jr., and R. Okamoto Osteocalcin immunolabeling during the alveolar healing process in ovariectomized rats treated with estrogen or raloxifene Bone 46 4 2010 1021 1029
13. A. Tomkinson, J. Reeve, R.W. Shaw, and B.S. Noble The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone J Clin Endocrinol Metab 82 9 1997 3128 3135 (Pubitemid 27385687)
14. A. Tomkinson, E.F. Gevers, J.M. Wit, J. Reeve, and B.S. Noble The role of estrogen in the control of rat osteocyte apoptosis J Bone Miner Res 13 8 1998 1243 1250 (Pubitemid 28373325)
15. P.G. Bradford, K.V. Gerace, R.L. Roland, and B.G. Chrzan Estrogen regulation of apoptosis in osteoblasts Physiol Behav 99 2 2010 181 185
16. V. Mann, C. Huber, G. Kogianni, F. Collins, and B. Noble The antioxidant effect of estrogen and selective estrogen receptor modulators in the inhibition of osteocyte apoptosis in vitro Bone 40 3 2007 674 684 (Pubitemid 46201947)
17. T. Nakamura, Y. Imai, T. Matsumoto, S. Sato, K. Takeuchi, and K. Igarashi Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts Cell 130 5 2007 811 823 (Pubitemid 47332572)
18. S.A. Krum, G.A. Miranda-Carboni, P.V. Hauschka, J.S. Carroll, T.F. Lane, and L.P. Freedman Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival EMBO 27 3 2008 535 545 (Pubitemid 351225684)
19. S. Kawamoto, S. Ejiri, E. Nagaoka, and H. Ozawa Effects of oestrogen deficiency on osteoclastogenesis in the rat periodontium Arch Oral Biol 47 1 2002 67 73 (Pubitemid 34052672)
20. T. Miyazaki, T. Matsunaga, S. Miyazaki, S. Hokari, and T. Komoda Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats J Cell Biochem 93 3 2004 503 512 (Pubitemid 44264186)
21. K.M. Prestwood, M. Gunness, D.B. Muchmore, Y. Lu, M. Wong, and L.G. Raisz A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women J Clin Endocrinol Metab 85 6 2000 2197 2202 (Pubitemid 32269244)
22. K.S. Tsai, M.L. Yen, H.A. Pan, M.H. Wu, W.C. Cheng, and S.H. Hsu Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women Osteoporos Int 12 12 2001 1020 1025 (Pubitemid 34105972)
23. L. Sliwiński, J. Folwarczna, B. Nowińska, U. Cegieła, M. Pytlik, and I. Kaczmarczyk-Sedlak A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system Acta Biochim Pol 56 2 2009 261 270
24. A. Bitto, B.P. Burnett, F. Polito, H. Marini, R.M. Levy, and M.A. Armbruster Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol Br J Pharmacol 155 6 2008 896 905
25. S. Bord, S. Beavan, D. Ireland, A. Horner, and J.E. Compston Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: role of locally produced growth factors Bone 29 3 2001 216 222 (Pubitemid 32823563)
26. P. Taxel, H. Kaneko, S.K. Lee, H.L. Aguila, L.G. Raisz, and J.A. Lorenzo Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study Osteoporos Int 19 2 2008 193 199
27. O.S. Narayana Murthy, S. Sengupta, S. Sharma, and M.M. Singh Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression J Steroid Biochem Mol Biol 100 4-5 2006 117 128 (Pubitemid 44177770)
28. D. Vega, N.M. Maalouf, and K. Sakhaee CLINICAL review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications J Clin Endocrinol Metab 92 12 2007 4514 4521 (Pubitemid 350223419)
29. Y.Y. Yuan, P.J. Kostenuik, M.S. Ominsky, S. Morony, S. Adamu, and D.T. Simionescu Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease Osteoporos Int 19 5 2008 625 635
30. J. Cheung, Y.T. Mak, S. Papaioannou, B.A. Evans, I. Fogelman, and G. Hampson Interleukin-6 (IL-6), IL-1, receptor activator od nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene J Endocrinol 177 3 2003 423 433 (Pubitemid 36722298)
31. V. Viereck, C. Gründker, S. Blaschke, B. Niederkleine, H. Siggelkow, and K.H. Frosch Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts J Clin Endocrinol Metab 88 9 2003 4206 4213 (Pubitemid 37153721)
32. E.M. Messalli, G. Mainini, C. Scaffa, A. Cafiero, P.L. Salzillo, and A. Ragucci Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women Maturitas 56 1 2007 38 44 (Pubitemid 44894788)
33. H. Michael, P.L. Härkönen, L. Kangas, H.K. Väänä nen, and T.A. Hentunen Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro Br J Pharmacol 151 3 2007 384 395 (Pubitemid 46842673)
34. B.J. Deroo, and K.S. Korach Estrogen receptors and human disease J Clin Invest 116 3 2006 561 570 (Pubitemid 43326860)
35. L.G. Raisz Pathogenesis of osteoporosis: concepts, conflicts, and prospects J Clin Invest 115 12 2005 3318 3325 (Pubitemid 43121814)
36. V.L. Baker, D. Leitman, and R.B. Jaffe Selective estrogen receptor modulators in reproductive medicine and biology Obstet Gynecol Surv 55 7 Suppl. 2 2000 S21 S47
37. M.Z. Yan, Y. Xu, Y.X. Gong, J.M. Liu, S.Y. Lu, and L. Huang Endocrine 37 1 2010 55 61
38. B.L. Riggs, and L.C. Hartmann Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice N Engl J Med 348 12 2003 618 629 (Pubitemid 36210865)
39. C. Huber, S. Collishaw, J.R. Mosley, J. Reeve, and B.S. Noble A selective estrogen receptor modulator inhibits osteocyte apoptosis during abrupt estrogen withdrawal: implications for bone quality maintenance Calcif Tissue Int 81 2 2007 139 144 (Pubitemid 47228736)